Please login to the form below
RNAi
This page shows the latest RNAi news and features for those working in and with pharma, biotech and healthcare.
China backs use of Roche’s Actemra for coronavirus
The two companies are already working together on RNAi drugs against hepatitis B virus.
Latest news
-
Alnylam scores EU approval for RNAi drug Givlaari
Alnylam has claimed European Commission approval for its second RNA interface (RNAi) drug Givlaari for acute hepatic porphyria. ... Alnylam’s first RNAi drug – Onpattro (patisiran) for rare disease hereditary ATTR amyloidosis – has a similar
-
Givlaari, Rybelsus lead crowded CHMP recommendations
Leading the flurry of recommendations was Givlaari (givosiran), Alnylam’s second RNAi drug, for acute hepatic porphyria.
-
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
RNA interference (RNAi) drug lumasiran works upstream of the deficient enzyme, switching off production of a substrate that it converts to oxalate. ... If approved, lumasiran would be Alnylam’s third RNAi drug after Onpattro (patisiran) for
-
Sanofi narrows focus, shedding diabetes and cardiovascular research
This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)
-
FDA clears Alnylam’s second RNAi drug for rare disease
Alnylam has claimed a second US approval for one of its RNA interference (RNAi) drugs, getting an FDA nod for acute hepatic porphyria drug Givlaari. ... RNAi drugs work by switching off genes that aren’t working properly, and Givlaari is only the
More from news
Approximately 10 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
With the introduction of new data analytics capabilities and broader adoption in the pharmaceutical industry, research platforms that heavily depend on data (eg, RNAi and CRISPR therapies) will likely increase their
-
20 for 2020 – Five pharma leaders to watch in 2020
More than a decade of research into its RNA interference (RNAi) drugs generated the first ever approval of a drug in this category towards the end of 2018, and the company ... 2020 will be a big year as it continues its transformation into a
-
Deal Watch October 2018
Dicerna/. Lilly. GalXC RNAi technology platform for targets in Cardiometabolic disease, neurodegeneration and pain.
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
This has been Alnylam’s story over the past 16 years, as it built on Andrew Fire and Craig Mello’s Nobel prize winning discovery that naturally occurring RNAi “silences” genes, ... Its RNAi technology can be used to target any gene expressed in
-
Boosting pharma’s metabolic rate
New frontiers such as cell therapy and RNAi are becoming therapeutic realities and exciting new challenges are coming over the horizon, creating a constantly shifting landscape that leaders must navigate.
More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Bruce Peacock joins Dicerna from Ophthotech
Massachusetts-headquartered Dicerna develops RNAi-based therapeutics with a focus on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
-
Silence appoints chief medical officer
These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
How do you define a biotech company?
This approach is particularly apparent in some of the recent examples of technology pioneered by biotech organisations, such as CAR-T technology (Novartis, Juno and Kite Pharma) and RNAi (Alnylam) where
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Nucleus Global announces a trio of promotions
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- New study identifies drugs that are safe to use in COVID-19 treatment
- Pfizer introduces new logo in a ‘shift from commerce to science’
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Say Communications
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
